
|Videos|December 26, 2014
Dr. Gomella on Labeling Low-Risk Prostate Cancer
Author(s)Leonard G. Gomella, MD
Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.
Advertisement
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.
Active surveillance is an appropriate treatment for the majority of those with Gleason six prostate cancer, but often the term ‘cancer’ makes patients feel like they need more aggressive treatment.
Overtreatment is a common problem, which may be solved by renaming the disease, says Gomella.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
2
Gilteritinib Yields Comparable Efficacy vs Midostaurin in Newly Diagnosed FLT3-Mutated AML but Fails to Meet Phase 3 Primary End Point
3
Dr Voorhees on Efficacy Data for Talquetamab-Based Combos in R/R Myeloma From MonumenTAL-3
4
Tuspetinib Plus Venetoclax and Azacitidine Is Safe and Effective Across Molecular Subgroups in Newly Diagnosed AML
5







































































